103 related articles for article (PubMed ID: 24580042)
1. Using patient-reported outcomes to improve the management of co-infection with HIV and HCV: the ANRS CO13 HEPAVIH cohort.
Marcellin F; Roux P; Winnock M; Lions C; Dabis F; Salmon-Ceron D; Loko MA; Spire B; Carrieri MP
Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):351-8. PubMed ID: 24580042
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of direct-acting antiviral regimens in HIV/HCV-co-infected patients - French ANRS CO13 HEPAVIH cohort.
Piroth L; Wittkop L; Lacombe K; Rosenthal E; Gilbert C; Miailhes P; Carrieri P; Chas J; Poizot-Martin I; Gervais A; Dominguez S; Neau D; Zucman D; Billaud E; Morlat P; Aumaitre H; Lascoux-Combe C; Simon A; Bouchaud O; Teicher E; Bani-Sadr F; Alric L; Vittecoq D; Boué F; Duvivier C; Valantin MA; Esterle L; Dabis F; Sogni P; Salmon D;
J Hepatol; 2017 Jul; 67(1):23-31. PubMed ID: 28235612
[TBL] [Abstract][Full Text] [Related]
3. Short article: Fatigue in the long term after HCV treatment in HIV-HCV-coinfected patients: functional limitations persist despite viral clearance in patients exposed to peg-interferon/ribavirin-containing regimens (ANRS CO13-HEPAVIH cohort).
Marcellin F; Protopopescu C; Poizot-Martin I; Miailhes P; Esterle L; Wittkop L; Spire B; Bocquier A; Salmon-Ceron D; Dabis F; Carrieri MP;
Eur J Gastroenterol Hepatol; 2016 Sep; 28(9):1003-7. PubMed ID: 27177169
[TBL] [Abstract][Full Text] [Related]
4. Evolution of patients' socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infected patients.
Yaya I; Roux P; Marcellin F; Wittkop L; Esterle L; Spire B; Dominguez S; Elegbe BA; Piroth L; Sogni P; Salmon-Ceron D; Carrieri MP;
PLoS One; 2018; 13(7):e0199874. PubMed ID: 29975764
[TBL] [Abstract][Full Text] [Related]
5. The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006-2010.
Loko MA; Salmon D; Carrieri P; Winnock M; Mora M; Merchadou L; Gillet S; Pambrun E; Delaune J; Valantin MA; Poizot-Martin I; Neau D; Bonnard P; Rosenthal E; Barange K; Morlat P; Lacombe K; Gervais A; Rouges F; See AB; Lascoux-Combe C; Vittecoq D; Goujard C; Duvivier C; Spire B; Izopet J; Sogni P; Serfaty L; Benhamou Y; Bani-Sadr F; Dabis F;
BMC Infect Dis; 2010 Oct; 10():303. PubMed ID: 20969743
[TBL] [Abstract][Full Text] [Related]
6. Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH).
Barré T; Zucman D; Marcellin F; Ramier C; Protopopescu C; Tardieu R; Ory K; Salmon-Céron D; Carrieri P;
J Viral Hepat; 2023 Nov; 30(11):897-900. PubMed ID: 37357886
[No Abstract] [Full Text] [Related]
7. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH).
Marcellin F; Di Beo V; Aumaitre H; Mora M; Wittkop L; Duvivier C; Protopopescu C; Lacombe K; Esterle L; Berenger C; Gilbert C; Bouchaud O; Poizot-Martin I; Sogni P; Salmon-Ceron D; Carrieri P;
J Hepatol; 2020 Mar; 72(3):588-591. PubMed ID: 31924411
[No Abstract] [Full Text] [Related]
8. Reply to: "Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)".
Evon DM; Sarkar S; Amador J; Lok AS; Sterling RK; Stewart PW; Reeve BB; Serper M; Reau N; Reddy KR; Di Bisceglie AM; Nelson DR; Golin CE; Lim JK; Fried MW
J Hepatol; 2020 Mar; 72(3):592-593. PubMed ID: 31889556
[No Abstract] [Full Text] [Related]
9. No significant effect of cannabis use on the count and percentage of circulating CD4 T-cells in HIV-HCV co-infected patients (ANRS CO13-HEPAVIH French cohort).
Marcellin F; Lions C; Rosenthal E; Roux P; Sogni P; Wittkop L; Protopopescu C; Spire B; Salmon-Ceron D; Dabis F; Carrieri MP;
Drug Alcohol Rev; 2017 Mar; 36(2):227-238. PubMed ID: 27073179
[TBL] [Abstract][Full Text] [Related]
10. Substance use and CD4/CD8 ratio in HIV/HCV co-infected people receiving direct-acting antiviral treatment (ANRS CO13 HEPAVIH): Authors' reply.
Rossotti R
J Viral Hepat; 2023 Nov; 30(11):901. PubMed ID: 37434464
[No Abstract] [Full Text] [Related]
11. HCV cure: an appropriate moment to reduce cannabis use in people living with HIV? (ANRS CO13 HEPAVIH data).
Barré T; Mercié P; Lions C; Miailhes P; Zucman D; Aumaître H; Esterle L; Sogni P; Carrieri P; Salmon-Céron D; Marcellin F;
AIDS Res Ther; 2022 Mar; 19(1):15. PubMed ID: 35292069
[TBL] [Abstract][Full Text] [Related]
12. Management and treatment of chronic hepatitis C in HIV patients.
Barreiro P; Vispo E; Labarga P; Soriano V
Semin Liver Dis; 2012 May; 32(2):138-46. PubMed ID: 22760653
[TBL] [Abstract][Full Text] [Related]
13. Role of treatment for depressive symptoms in relieving the impact of fatigue in HIV-HCV co-infected patients: ANRS Co13 Hepavih, France, 2006-2008.
Michel L; Villes V; Dabis F; Spire B; Winnock M; Loko MA; Poizot-Martin I; Valantin MA; Bonnard P; Salmon-Céron D; Carrieri MP;
J Viral Hepat; 2010 Sep; 17(9):650-60. PubMed ID: 20002565
[TBL] [Abstract][Full Text] [Related]
14. Psychiatric and substance use disorders in HIV/hepatitis C virus (HCV)-coinfected patients: does HCV clearance matter? [Agence Nationale de Recherche sur le SIDA et les Hépatites Virales (ANRS) HEPAVIH CO13 cohort].
Michel L; Lions C; Winnock M; Lang JP; Loko MA; Rosenthal E; Marchou B; Valantin MA; Morlat P; Roux P; Sogni P; Spire B; Poizot-Martin I; Lacombe K; Lascoux-Combe C; Duvivier C; Neau D; Dabis F; Salmon-Ceron D; Carrieri MP;
HIV Med; 2016 Nov; 17(10):758-765. PubMed ID: 27187027
[TBL] [Abstract][Full Text] [Related]
15. Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.
Rodríguez-Torres M
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1117-28. PubMed ID: 23199398
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous and post-treatment HCV clearance: relationships with health-related quality of life in HIV infection (ANRS-VESPA2 study).
Marcellin F; Demoulin B; Spire B; Suzan-Monti M; Roux P; Protopopescu C; Sagaon-Teyssier L; Duracinsky M; Dray-Spira R; Carrieri MP;
Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):701-13. PubMed ID: 25723557
[TBL] [Abstract][Full Text] [Related]
17. Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort).
Costa M; Rojas TR; Lacoste D; Villes V; Aumaitre H; Protopopescu C; Yaya I; Wittkop L; Krause J; Salmon-Céron D; Marcellin F; Sogni P; Carrieri MP;
Eur J Gastroenterol Hepatol; 2019 Dec; 31(12):1508-1517. PubMed ID: 31094856
[TBL] [Abstract][Full Text] [Related]
18. High HCV treatment uptake in the Swedish HIV/HCV co-infected cohort.
Stenkvist J; Weiland O; Sönnerborg A; Blaxhult A; Falconer K
Scand J Infect Dis; 2014 Sep; 46(9):624-32. PubMed ID: 24984040
[TBL] [Abstract][Full Text] [Related]
19. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
Rodríguez-Torres M
Curr Opin Infect Dis; 2013 Feb; 26(1):50-7. PubMed ID: 23242341
[TBL] [Abstract][Full Text] [Related]
20. Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.
Roux P; Fugon L; Winnock M; Salmon-Céron D; Lacombe K; Sogni P; Spire B; Dabis F; Carrieri MP;
Addiction; 2012 Jan; 107(1):152-9. PubMed ID: 21819472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
